> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Harmony Biosciences Picks COO Peter Anastasiou To Succeed CEO Jeffrey Dayno On January 1
- URL: https://www.bullished.co/harmony-biosciences-picks-coo-peter-anastasiou-to-succeed-ceo-jeffrey-dayno-on-january-1-8b9c8525/
- Published: 2026-10-13T12:06:34.000Z
- Updated: 2026-10-28T22:21:34.000Z
- Description: Dayno retires December 31 after a nine-year tenure, and the company kept its $1.0 billion to $1.04 billion 2026 WAKIX revenue guidance.
- Author: Matteo Parrino
- Tags: SEC Filings, HRMY, Industry: Healthcare

Harmony Biosciences named Chief Operating Officer Peter Anastasiou its next president and CEO, [effective January 1, 2027](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926115282/hrmy-20261012x8k.htm?ref=bullished.co), according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Tuesday. He succeeds Jeffrey Dayno, who retires and leaves the board on December 31, 2026.

## What the 8-K says

The company announced the change on October 12 in a press release attached to the filing. It described the move as part of the board's succession planning.

Dayno will stay on as a non-executive advisor through 2027\. The press release says he spent nine years at the company, including time as chief medical officer.

Anastasiou, 55, has been COO since April 2026\. He sat on Harmony's board from November 2023 to April 2026, and the board will also seat him as a Class I director on January 1, with a term running to the 2027 annual meeting. He will receive no extra pay for board service.

Before Harmony, he was CEO of Capsida Biotherapeutics from January 2022 to October 2025\. The press release says he raised more than $165 million there and secured partnerships with AbbVie and Lilly.

From November 2009 to December 2021 he worked at Lundbeck, finishing as executive vice president and president of North America. The release says he led about 1,200 employees and delivered annual net revenues above $1.5 billion.

## What it changes for holders

The company said it expects no change in the timing of key commercial and pipeline milestones. It [reiterated](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926115282/hrmy-ex99d1.htm?ref=bullished.co) full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

It also said it is on track to report data from the multiple ascending dose study of its experimental drug BP-205 in the fourth quarter of 2026.

Chairman Jeffrey Aronin, the company's founder, said Anastasiou "has a deep understanding of our business." Anastasiou said Harmony has "a strong balance sheet that allows us to be self-funded."

Harmony shares closed at $38.23 at Monday's close, down 5.09% on the session, according to market data. The material does not tie that move to the announcement.

## What to watch

The BP-205 study data are due in the fourth quarter, before Anastasiou takes over.

The BP-205 readout is the first milestone Anastasiou will inherit as CEO.

Learn

- [Item 5.02: directors and officers leave or join, or executive pay is set →](https://www.bullished.co/learn/8-k-items-explained/#item-502-directors-and-officers-leave-or-join-or-executive-pay-is-set)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Harmony Biosciences Holdings, Inc. (HRMY)](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926115282/hrmy-20261012x8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit hrmy-ex99d1.htm — Harmony Biosciences Holdings, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926115282/hrmy-ex99d1.htm?ref=bullished.co) — SEC EDGAR
- [Harmony Biosciences Stock Dives As CEO Jeffrey Dayno Plans His Exit | Investor's Business Daily](https://www.investors.com/news/technology/harmony-biosciences-stock-jeffrey-dayno-ceo-transition/?ref=bullished.co) — investors.com